ICER Fumbles Rheumatoid Arthritis Report
The controversial Institute for Clinical and Economic Review has done something unprecedented: admitted it’s wrong.
Medicaid Waiver Rejection Signals Win for Patient Access
Massachusetts Medicaid patients are breathing a collective sigh of relief.
Does ICER’s Model Work for Rheumatoid Arthritis Treatments?
The Institute for Clinical and Economic Review’s newest cost-effectiveness report underscores just how far economic modeling sometimes diverges from patients’ reality, explained the Institute for Patient Access in a February 17 letter. The report analyzes rheumatoid arthritis treatments’ value by modeling expenses for simulated patients over a lifetime on certain treatments.
